Satellos Bioscience Inc Com V.ICO

RE:RE:RE:RE:RE:RE:The next leg up

[moneystarved]

diamond,

It appears people had better places for their money over the last year, then waiting for these results.  But it is fairly apparent, money wants back in, as we lead up to the results (no more sitting on the sidelines as it is go time).

A great example of the potential for ICO,  is Regeneron's bread winner drug Eyelea.

My share price estimate is based on a market cap of $130,000,000 to $175,000,000.

67,811,230	shares
15765918	warrants
2,965,000	options
86,542,148	Total

=$1.50-$2 psf fully diluted

This was from Andrew Rae a while ago.... "Given the explosive increase in diabetic population and the “aging” demographic, the market for iC-007 is significant. By way of comparison, Eylea, a product that was recently introduced to the wet age-related macular degeneration market (Wet AMD), a “sister” disease to DME, posted revenue of about $838 million in 2012, the first year of introduction, and $314 million for Q1 2013. And that was based simply on being able to reduce the frequency of patient injections from once a month – the typical treatment regime using the current standard of care, a drug called Lucentis – to once every two months using Eylea. We believe iCo-007 can reduce the injection frequency even further, and has other advantages in product differentiation as well."

Note, just released, eyelea's sales have actually increased 67% last year to $1.4billion (from $800m in its first year).

Parallels to ICO?  "Phase II clinical trials were conducted from April 2006 to August 2008. It was a randomised, controlled study which enrolled 159 patients with wet AMD. The primary outcome measure of the study was finding the mean change in central retinal / lesion thickness (CR/LT) from the baseline at week 12."

If you dont think a drug company would pay $130m-$175m for a potentially easier to market drug (injection once every three months),  Whose sales are growing at over 50% per year (and over $1.4billin in sales per year).  Seems like a reasonable valuation.  After results, if confirm efficacy, one would expect the valuation to be much much higher?

The value of regereron's shares have increased over 18x's from their phase 2 trials to now.  We also have a similar sized phase 2 study, although Eyelea did not (that i know of) have the partnership with JDRF that ICO does.

I am not an expert, but I do see the huge huge potential here.  Is there risk, of course, but I also see that a lot of it has already been mitigated.

You need to do what is right for your own financial situation.  This is what is right for mine.

Good luck,
imo ms